The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis

Recombinant human erythropoietin has proved to be effective to treat anemia of end-stage renal disease (ESRD). The aim of this study was to assess the efficacy and safety profile of Epotin, a rHuEPO produced in the Middle East. One hundred thirty patients with Hct

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation proceedings 2004-07, Vol.36 (6), p.1805-1811
Hauptverfasser:	Abbas, E E, Afioni, N, Al Wakeel, J, Bakr, M A, Dham, R, Donia, A, Droubi, N, Khidir, E, Mathew, C M, Mitwali, A H, Naga, S, Pingle, A, Rashed, A, Roshdy, A, Shaheen, F, Shaibani, B, Shaibani, F M, Shaker, D S, Sheiban, A, Solieman, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anemia - drug therapy Anemia - etiology Epoetin Alfa Erythropoietin - therapeutic use Female Ferritins - blood Hematinics - therapeutic use Hematocrit Humans Iron - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Male Middle East Recombinant Proteins Renal Dialysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recombinant human erythropoietin has proved to be effective to treat anemia of end-stage renal disease (ESRD). The aim of this study was to assess the efficacy and safety profile of Epotin, a rHuEPO produced in the Middle East. One hundred thirty patients with Hct
ISSN:	0041-1345